Female reproductive factors, menopausal hormone use, and Parkinson's disease

Movement Disorders

Volumn 29, Issue 7, 2014, Pages 889-896

  Liu, Rui ^a   Baird, Donna ^a   Park, Yikyung ^b   Freedman, Neal D ^b   Huang, Xuemei ^c   Hollenbeck, Albert ^d   Blair, Aaron ^b   Chen, Honglei ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d AARP   (United States)

Author keywords

Cohort studies; Menopausal hormone therapy; Parkinson's disease; Reproductive factors

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FEMALE GENITAL SYSTEM; FOLLOW UP; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSAL SYNDROME; MENOPAUSE; ORAL CONTRACEPTIVE USE; PARITY; PARKINSON DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; COMPLICATION; DIET; HORMONE SUBSTITUTION; MIDDLE AGED; PHYSIOLOGY; REPRODUCTION; REPRODUCTIVE HISTORY; RISK;

AGED; DIET; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; REPRODUCTION; REPRODUCTIVE HISTORY; RISK;

EID: 84902175620     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25771     Document Type: Article

References (35)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
2. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:819-824.
3. Dluzen DE, McDermott JL. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease. J Gend Specif Med 2000;3:36-42.
4. Miller IN, Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord 2010;25:2695-2703.
5. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin Exp Pharmacol Physiol 2007;34:555-565.
6. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003;110:1215-1224.
7. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385-394.
8. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol 1999;22:93-97.
9. The Parkinson Study Group POETRY Investigators. A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease. Parkinsonism Relat Disord 2011;17:757-760.
10. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999;53:91-95.
11. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292-2298.
12. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005;65:383-390.
13. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886-888.
14. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003;60:790-795.
15. Nicoletti A, Nicoletti G, Arabia G, et al. Reproductive factors and Parkinson's disease: a multicenter case-control study. Mov Disord 2011;26:2563-2566.
16. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 2009;24:1359-1365.
17. Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004;160:977-984.
18. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
19. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50:1141-1143.
20. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004;62:2010-2014.
21. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 2001;154:1119-1125.
22. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010;74:878-884.
23. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-209.
24. Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 1991;81:90-96.
25. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
26. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011;1379:188-198.
27. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001;41:131-138.
28. Dluzen DE, Ramirez VD. Intermittent infusion of progesterone potentiates whereas continuous infusion reduces amphetamine-stimulated dopamine release from ovariectomized estrogen-primed rat striatal fragments superfused in vitro. Brain Res 1987;406:1-9.
29. Singh M. Mechanisms of progesterone-induced neuroprotection. Ann N Y Acad Sci 2005;1052:145-151.
30. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662.
31. Chubak J, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev 2004;13:1296-1301.
32. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011;76:863-869.
33. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011;119:866-872.
34. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
35. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.